PRISM MediaWire

BioStem Technologies Reports Third Quarter 2023 Operating and Financial Results

Company to Host a Conference Call and Webcast on November 14, 2023, at 10:30 am EDT

14 November 2023

Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug

“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” ~Dr. Michael Chancellor, Chief Medical Officer at Lipel...

10 November 2023

Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024--Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET-

9 November 2023

BioStem Technologies Awarded Q Code for VENDAJE AC®

“Securing the CMS Q code for our VENDAJE AC® tissue allograft marks yet another win for BioStem Technologies and ensures broader access to another top-tier wound care product within our portfolio.” ~BioStem Technologies CEO, Jason Matuszewski

8 November 2023

BioStem Technologies Awarded Q Code for VENDAJE AC® Line from Centers for Medicare and Medicaid Services

POMPANO BEACH, FLORIDA, November 8, 2023 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announ...

8 November 2023

PRISM MarketView Insight: Is It Time to Invest in Small-Cap Stocks?

NEW YORK, NY, November 7, 2023 - PRISM MediaWire - As the Russell 2000 recently recorded its best week in over two years, investors are turning their attention to the potential end of the Federal Reserve’s interest rate hike cycle. This shift in sentiment has sparked a ...

7 November 2023

BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

POMPANO BEACH, FLORIDA, November 6, 2023 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced to...

6 November 2023

BioStem Technologies Closes Oversubscribed $2M Private Placement

POMPANO BEACH, FLORIDA, November 3, 2023 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announ...

4 November 2023

Oncocyte to Announce Third Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET

4 November 2023

Remsleep Holdings Inc.’s DeltaWave Mask Moves to Substantive Review of FDA 510k Process

Tampa, FL, November 2, 2023 - PRISM MediaWire - RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, is pleased to announce its DeltaWave mask has move...

2 November 2023